Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.
Hubertus Wald Universitäres Cancer Center Hamburg (UCCH), Martinistraße 54, 20246, Hamburg, Germany.
Qual Life Res. 2023 May;32(5):1427-1446. doi: 10.1007/s11136-022-03300-1. Epub 2022 Nov 28.
Clinical data on the modern topic fasting among cancer patients are rare. This review aimed to summarise published clinical data on fasting and its effects on patients undergoing chemotherapy and therefore to give some directions in advising patients with the desire to fast.
A systematic search was conducted searching five electronic databases (Embase, Cochrane, PsychInfo, CINAHL and Medline) to find studies concerning the use, effectiveness and potential harm of fasting during therapy on cancer patients. The main endpoints were quality of life, side effects and toxicities of the fasting intervention.
The search results totaled 3983 hits. After systematic sorting according to standardised pre-defined criteria, nine publications which covered eight studies with 379 patients were included in this systematic review. The majority of the patients included were diagnosed with breast- and gynaecological cancers. Fasting duration and timepoints ranged significantly (24-140 h before, and on the day of, chemotherapy to 56 h after chemotherapy). In one study patients were fasting before cancer surgery. The studies were mostly low to moderate quality and reported heterogeneous results. Overall, the studies were insufficiently powered to detect significant effects on the predefined endpoints.
Fasting for short periods does not have any beneficial effect on the quality of life of cancer patients during treatment. Evidence on fasting regimes reducing side effects and toxicities of chemotherapy is missing. In contrast, as the negative effects of unintentional weight loss are known to impact clinical outcomes severely, fasting is not indicated in this context.
关于癌症患者禁食这一现代话题的临床数据较为匮乏。本综述旨在总结已发表的关于禁食及其对接受化疗的患者影响的临床数据,从而为有禁食意愿的患者提供一些建议。
系统检索了五个电子数据库(Embase、Cochrane、PsychInfo、CINAHL 和 Medline),以查找关于癌症患者在治疗期间禁食的使用、效果和潜在危害的研究。主要终点是禁食干预对生活质量、副作用和毒性的影响。
检索结果总计 3983 条。根据预先设定的标准进行系统排序后,纳入了 9 篇文献,其中涵盖了 8 项研究,共 379 例患者。纳入的患者多数被诊断为乳腺癌和妇科癌症。禁食持续时间和时间点差异显著(24-140 小时,在化疗前,以及在化疗当天至化疗后 56 小时)。在一项研究中,患者在癌症手术前禁食。这些研究的质量大多为低至中度,报告结果存在异质性。总体而言,这些研究的效力不足以检测到对预先设定终点的显著影响。
在治疗期间,短暂禁食对癌症患者的生活质量没有任何有益影响。缺乏关于禁食方案减少化疗副作用和毒性的证据。相反,由于无意识体重减轻的负面影响已知会严重影响临床结果,因此在这种情况下禁食是不被推荐的。